New study tracks blood sugar in liver disease patients on common drug
NCT ID NCT07629128
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how a type of medication called PPAR agonists affects blood sugar levels in 30 adults with primary biliary cholangitis (PBC), a chronic liver disease. Researchers will measure changes in blood sugar and other metabolic markers over three months. The goal is to better understand how to manage both liver and metabolic health in these patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLOOD SUGAR; HIGH are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fondazione Policlinico Universitario A. Gemelli IRCCS,UOC Medicina Interna e Gastroenterologia,Largo A. Gemelli
Roma, 00168, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can extra doses of an old drug reverse liver scarring?
- Can Weight-Loss surgery beat drugs for advanced liver damage?
- Artificial intelligence may help decide who gets a liver first
- AI may outsmart current system for liver transplant priority
- Navy beans take on fatty liver: a diet swap put to the test
- Could a cholesterol drug and a bile acid pill help reverse liver scarring?